X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
Details:
The Company now anticipates it will approach breakeven cash flow in the second half of 2022 without the cash flows from its interest in GSK's Trelegy Ellipta (fluticasone furoate) royalties, driven by disciplined spending within R&D and the growth of YUPELRI®.
Lead Product(s): Fluticasone Furoate,Umeclidinium Bromide,Vilanterol Trifenatate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Trelegy Ellipta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Royalty Pharma
Deal Size: $1,550.0 million Upfront Cash: $1,100.0 million
Deal Type: Divestment July 13, 2022
Details:
Trelegy Ellipta (fluticasone furoate) is a glucocorticoid receptor binder which is approved in combination with umeclidinium & vilanterol for the treatment of chronic obstructive pulmonary disease.
Lead Product(s): Fluticasone Furoate,Umeclidinium Bromide,Vilanterol Trifenatate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Trelegy Ellipta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
Trelegy Ellipta (fluticasone furoate) is a glucocorticoid receptor binder which is being evaluated in phase 4 clinical trials in combination with umeclidinium & vilanterol for the treatment of chronic obstructive pulmonary disease.
Lead Product(s): Fluticasone Furoate,Umeclidinium Bromide,Vilanterol Trifenatate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Trelegy Ellipta
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2021
Details:
The European Union’s healthcare regulator the European Medicines Agency (EMA) has decided against a label expansion for GlaxoSmithKline (GSK)’s drug Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to include asthma.
Lead Product(s): Fluticasone Furoate,Umeclidinium Bromide,Vilanterol Trifenatate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Trelegy Ellipta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2021
Details:
FDA has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with COPD.
Lead Product(s): Fluticasone Furoate,Umeclidinium Bromide,Vilanterol Trifenatate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Trelegy Ellipta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2020
Details:
Trelegy Ellipta (fluticasone furoate) is a glucocorticoid receptor binder which is under phase 3 clinical development in combination with umeclidinium & vilanterol for the treatment of adult patients with Asthma.
Lead Product(s): Fluticasone Furoate,Umeclidinium Bromide,Vilanterol Trifenatate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Trelegy Ellipta
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
